ESOPHAGEAL SQUAMOUS CELL CANCER
Clinical trials for ESOPHAGEAL SQUAMOUS CELL CANCER explained in plain language.
Never miss a new study
Get alerted when new ESOPHAGEAL SQUAMOUS CELL CANCER trials appear
Sign up with your email to follow new studies for ESOPHAGEAL SQUAMOUS CELL CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug XB010 shows promise in early trial for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage study tests a new drug called XB010, alone or with another drug (pembrolizumab), in people with advanced solid tumors that have not responded to other treatments. The main goals are to find the safest dose and check for side effects. About 396 adults with cancers…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CANCER
Phase: PHASE1 • Sponsor: Exelixis • Aim: Disease control
Last updated May 16, 2026 22:30 UTC
-
New drug KIVU-107 targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis study tests a new drug called KIVU-107 in people with advanced solid tumors that have stopped responding to standard treatments. The drug is designed to target and kill cancer cells while limiting harm to healthy cells. The main goals are to find the safest dose and check fo…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CANCER
Phase: PHASE1 • Sponsor: Kivu Bioscience Inc. • Aim: Disease control
Last updated May 12, 2026 13:42 UTC